MBRMGEN@EC2607A

Citi Reiterates Buy Rating on RemeGen, Bullish on Pipeline’s Global Potential

JPMorgan Chase Maintains Buy Rating and Target Price for RemeGen

Rongchang Biotechnology expects a net profit of 716 million RMB in 2025

Rongchang Biotech Expected to Turn Profitable in 2025

Chinese Pharma Companies Complete 10 Overseas Licensing Deals in January

BOCOMINTL Maintains Buy Rating on RemeGen with Target Price of HKD 136

Rongchang Bio Repurchased 194,100 Shares for the First Time

Rongchang Biotechnology Adjusts Repurchase Price Ceiling to 116 Yuan

Rongchang Biotechnology signs licensing agreements with Vor Biopharma and AbbVie

JPMorgan Raises Target Price for RemeGen to HKD 136, Maintains 'Buy' Rating

AbbVie and RemeGen Enter into RC148 Bispecific Antibody License Agreement

Rongchang Biotechnology has not yet commenced share repurchase

Rongchang Bio Receives a RMB 36 Million Loan Commitment from China Merchants Bank

Rongchang Biotechnology Plans to Repurchase A-shares for Up to 40 Million Yuan

BlackRock cuts holdings in RemeGen by 185,500 shares

East China Securities Issues Buy Rating for Rongchang Biotechnology

CFC 上调荣昌生物目标价及盈利预测

Rongchang Biotech Reports Strong Revenue Growth but Persistent Losses in Q3 2025

荣昌生物 3Q25 Performance Slightly Better Than Expected, PD-1/VEGF Dual Antibody Development Strategy Revealed

Rongchang Biotech Signs 400 Million RMB Wealth Management Product Agreement with SPDB Yantai Branch

DAISHOMICROLINE

PUTIAN COMM

MOBI DEV

NANFANG COMM

ADD NEW ENERGY

ELIFE HLDGS

SIWI SCI & TECH

DTXS SILK ROAD

SANDMARTIN INTL

HAO BAI INTL

03666

09995

09992

520920

00HSI

513130

688331

STECH

00772

03032

36Kr learned that the Hang Seng Index rose 0.54% during the midday break, and the Hang Seng Technology Index rose 0.84%; the consumer, pharmaceutical and biotechnology, and media sectors led the gains, with CHINA LIT rising over 15%, RemeGen rising over 6%, and POP MART rising over 4%; the household goods, consumer services, and retail sectors saw the largest declines, with SHANGHAI XNG falling over 17%, Beijing Jingkelong falling over 6%, and Shangmei Co., Ltd. falling over 2%; southbound funds had a net purchase of HKD 1.145 billion

36Kr

SHANGHAI XNG

REMEGEN

POP MART

Tianhong Hang Seng TECH ETF(QDII)

Hang Seng Index

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

RemeGen

Hang Seng TECH Index

CHINA LIT

HSTECH ETF

The Hang Seng Index rose 0.54% at midday, and the Hang Seng TECH Index rose 0.84%

516500

159849

560600

588130

516820

RemeGen released a positive profit forecast, expecting a net profit of approximately 716 million RMB for the fiscal year 2025, compared to a loss of 1.468 billion RMB in the previous year. The turnaround from loss to profit is mainly attributed to the rapid growth of core products Teprotumumab and Vadastuximab, as well as increased technology licensing revenue from collaboration with Vor BioPharma Inc. The company reduced costs by optimizing management and production processes, with an annual operating revenue of approximately 3.25 billion RMB, an increase of 89%

AASTOCKS

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Vor BioPharma

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

"Profit Alert" RemeGen's revenue increased by 89%, forecasting an annual profit of over 700 million RMB

159506

159615

513120

520880

RemeGen Co. Ltd. forecasts a profit turnaround in 2025, projecting operating revenue of approximately RMB3.25 billion, an 89% increase year-on-year, and a net profit of around RMB716 million. This improvement is attributed to strong sales of its biologic drugs, a global licensing deal with Vor Biopharma, and internal cost efficiencies. The company expects to shift from a loss in 2024 to profitability in 2025, enhancing its market position. The current analyst rating for RemeGen stock (HK:9995) is a Hold with a price target of HK$88.00.

Tip Ranks

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Research Sector 100 ETF

Huaan Hang Seng Biotech ETF

RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal

RemeGen Co. Ltd. expects a net profit of RMB716 million for 2025, driven by an 89% revenue surge. The company attributes this improvement to a better cost structure, enhanced gross profit margins, and reduced sales expenses. Excluding non-recurring items, RemeGen anticipates a turnaround in net profit for the year, reflecting significant business performance enhancement. These figures are preliminary estimates and highlight the company's positive trajectory.

Reuters

RemeGen Expects 2025 Net Profit to Reach RMB716 Million on 89% Revenue Surge

516930

From January 1, 2026 to January 20, 2026, the company has repurchased 194,144 shares, representing 0.04% for CNY 20 million. With this, the company has completed the repurchase of 194,144 shares, representing 0.04% for CNY 20 million under the buyback announced on December 15, 2025.

marketscreener

Minsheng Royal CSI Biotechnology Theme ETF

Tranche Update on RemeGen Co., Ltd.'s Equity Buyback Plan announced on December 15, 2025.

In a report released yesterday, from BOCOM International Holdings Company maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$136.00.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential RemeGen Co. Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$99.54.

BOCOM International Holdings Company Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)

In a report released yesterday, from Zhongtai Securities upgraded RemeGen Co. Ltd. Class H to a Buy, with a price target of HK$114.00.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RemeGen Co. Ltd. Class H with a HK$99.54 average price target.

RemeGen Co. Ltd. Class H (9995) was upgraded to a Buy Rating at Zhongtai Securities

ABBV

On January 12, 2026, AbbVie and RemeGen entered an exclusive licensing agreement for RC148, a bispecific antibody, with AbbVie paying $650 million upfront. This partnership enhances RemeGen's investment narrative by extending its cash runway and reducing balance sheet risk. The focus now shifts to RC148's development and other key programs, while concerns about execution risk and high valuations remain. RemeGen's shares are seen as potentially undervalued by 14%, with community estimates suggesting a fair value of HK$114.07.

Simplywall

Abbvie

The Bull Case For RemeGen (SEHK:9995) Could Change Following AbbVie’s RC148 Licensing Deal - Learn Why

The J.P. Morgan Healthcare Conference 2026 highlighted a shift in biopharmaceutical deal-making, focusing on internal pipeline prioritization and licensing agreements rather than large M&As. Despite the absence of mega-deals, optimism remains due to a 59.3% increase in M&A deal value in Q4 2025 and a 157% rise in IPO volume. Notable licensing agreements were announced, including AbbVie's $5.6bn deal with RemeGen and Novartis's agreements totaling over $1.6bn. Industry experts emphasized the need for US investment in R&D to maintain market dominance against China, while demand for innovative drug development continues to grow.

Pharmaceutical Technology

JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As

RemeGen Lifts Price Cap on Share Repurchase

RemeGen Lifts Price Cap on Share Repurchase

China Merchants Jinling International released a research report, raising the target price for RemeGen to 136 yuan and adjusting the revenue forecast for 2026 to 2027. RemeGen has reached an exclusive licensing agreement with AbbVie, granting AbbVie the rights to develop, produce, and commercialize RC148 outside of Greater China. RemeGen will receive an upfront payment of $650 million and up to $4.95 billion in milestone payments. The firm believes this transaction has limited short-term impact on KANGFANG and SANSHENG

CITIC International raised the target price of RemeGen to 136 yuan and adjusted the revenue forecast for this year and next year

02418

01921

00147

02617

06616

00800

06086

09961

06938

DEEWIN(02418) fell 23.56%, with a trading turnover 18.9 Million HKD, and a year-to-date fell 63.6%. DALIPAL HLDG(01921) fell 15.58%, with a trading turnover 51.4 Million HKD, and a year-to-date fell 11.3%. IB SETTLEMENT(00147) fell 11.73%, with a trading turnover 6.8 Million HKD, and a year-to-date rose 0%.

Top Gainers & Losers

DEEWIN

DALIPAL HLDG

IB SETTLEMENT

TRANSTHERA-B

GLOBAL NEW MAT

WERIDE-W

FANGZHOU JIANKE

TRIP.COM-S

RIBOLIFE-B

Top 10 HK Stock Losers (1.14)

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

WUXI BIO

WuXi Biologics

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

MIXUE GROUP

GUMING

AIA Group

LIANLIAN

OSL GROUP

PICC P&C

MAO GEPING

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

MBRMGEN@EC2607A(24399.HK)

The Hang Seng Index rose 0.54% at midday, and the Hang Seng TECH Index rose 0.84%

"Profit Alert" RemeGen's revenue increased by 89%, forecasting an annual profit of over 700 million RMB

RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal

RemeGen Expects 2025 Net Profit to Reach RMB716 Million on 89% Revenue Surge

Tranche Update on RemeGen Co., Ltd.'s Equity Buyback Plan announced on December 15, 2025.